Organometallic compounds with biological activity: A very selective and highly potent cellular inhibitor for glycogen synthase kinase 3

ChemBioChem

Volumn 7, Issue 9, 2006, Pages 1443-1450

  Atilla Gokcumen, G Ekin ^a   Williams, Douglas S ^a   Bregman, Howard ^a   Pagano, Nicholas ^a   Meggers, Eric ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Glycogen snythase kinase 3; Medicinal chemistry; Organometallic compaounds; Protein kinases; Ruthenium

Indexed keywords

6 BROMOINDIRUBIN 3' OXIME; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; KENPAULLONE; ORGANOMETALLIC COMPOUND; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELL STRAIN HEK293; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR PROBE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ZEBRA FISH;

ANIMALS; BETA CATENIN; CATALYSIS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; EMBRYO, NONMAMMALIAN; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASE 3; HELA CELLS; HUMANS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RUTHENIUM; STEREOISOMERISM; TCF TRANSCRIPTION FACTORS; ZEBRAFISH;

DANIO RERIO;

EID: 33748599842     PISSN: 14394227     EISSN: 14397633     Source Type: Journal    
DOI: 10.1002/cbic.200600117     Document Type: Article

References (65)

1. For chemical genetics, see: a) S. L. Schreiber, Bioorg. Med. Chem. 1998, 6, 1127-1152;
2. b) T. U. Mayer, Trends Cell Biol. 2003, 13, 270-277;
3. c) I. Smukste, B. R. Stockwell, Annu. Rev. Genomics Hum. Genet. 2005, 6, 261-286.
4. For metal-based drugs, see: a) C. Orvig, M. J. Abrams, Chem. Rev. 1999, 99, 2201-2842;
5. b) Z. Guo, P. J. Sadler, Angew. Chem. 1999, 111, 1610-1630;
6. Angew. Chem. Int. Ed. 1999, 38, 1512-1531;
7. c) N. Farrell, Coord. Chem. Rev. 2002, 232, 1-230;
8. d) I. Ott, B. Kircher, R. Gust, J. Inorg. Biochem. 2004, 98, 485-489;
9. e) C. S. Allardyce, A. Dorcier, C. Scolaro, P. J. Dyson, Appl. Organomet. Chem. 2005, 19, 1-10;
10. f) P. J. Dyson, G. Sava, Dalton Trans. 2006, 1929-1933;
11. g) U. Schatzschneider, N. Metzler-Nolte, Angew. Chem. 2006, 118, 1534-1537;
12. Angew. Chem. Int. Ed. 2006, 45, 1504-1507.
13. For metal complexes as enzyme inhibitors, see: A. Y. Louie, T. J. Meade, Chem. Rev. 1999, 99, 2711-2734.
14. For bioorganometallic chemistry, see: a) K. Severin, R. Bergs, W. Beck, Angew. Chem. 1998, 110, 1722-1734;
15. Angew. Chem. Int. Ed. 1998, 37, 1634-1654;
16. b) D. B. Grotjahn, Coord. Chem. Rev. 1999, 190, 1125-1141;
17. c) G. Jaouen (Ed.), J. Organomet. Chem. 1999, 589, 1-126;
18. d) N. Metzler-Nolte, Angew. Chem. 2001, 113, 1072-1076;
19. Angew. Chem. Int. Ed. 2001, 40, 1040-1043;
20. e) R. H. Fish, G. Jaouen, Organometallics 2003, 22, 2166-2177;
21. f) R. Stodt, S. Gencaslan, I. M. Müller, W.S. Sheldrick, Eur. J. Inorg. Chem. 2003, 1873-1882;
22. g) D. Schlawe, A. Majdalani, J. Velcicky, E. Heßler, T. Wieder, A. Prokop, H.-G. Schmalz, Angew. Chem. 2004, 116, 1763-1766;
23. Angew. Chem. Int. Ed. 2004, 43, 1731-1734;
24. h) D. R. Van Staveren, N. Metzler-Nolte, Chem. Rev. 2004, 104, 5931-5985;
25. i) Bioorganometallicks (Ed.; G. Jaouen), Wiley-VCH, Weinheim, 2005.
26. H. Bregman, D. S. Williams, G. E. Atilla, P. J. Carroll, E. Meggers, J. Am. Chem. Soc. 2004, 126, 13594-13595.
27. D. S. Williams, G. E. Atilla, H. Bregman, A. Arzoumanian, P. S. Klein, E. Meggers, Angew. Chem. 2005, 117, 2020-2023;
28. Angew. Chem. Int. Ed. 2005, 44, 1984-1987.
29. H. Bregman, D. S. Williams, E. Meggers, Synthesis 2005, 1521-1527.
30. H. Bregman, P. J. Carroll, E. Meggers, J. Am. Chem. Soc. 2006, 128, 877-884.
31. J. É. Debreczeni, A. N. Bullock, G. E. Atilla, D. S. Williams, H. Bregman, S. Knapp, E. Meggers, Angew. Chem. 2006, 118, 1610-1615;
32. Angew. Chem. Int. Ed. 2006, 45, 1580-1585.
33. For chemical space, see: C. M. Dobson, Nature 2004, 432, 824-828.
34. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, Science 2002, 298, 1912-1934.
35. a) S. R. Hubbard, J. H. Till, Annu. Rev. Biochem. 2000, 69, 373-398;
36. b) M. Huse, J. Kuriyan, Cell 2002, 109, 275-282.
37. For protein kinase inhibitor scaffolds, see: a) C. Garcia- Echeverría, P. Traxler, D. B. Evans, Med. Res. Rev. 2000, 20, 28-57;
38. b) A. J. Bridges, Chem. Rev. 2001, 101, 2541-2571.
39. For protein kinase inhibitor selectivities, see: a) S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Biochem. J. 2000, 351, 95-105;
40. b) J. Bain, H. McLauchlan, M. Elliott, P. Cohen, Biochem. J. 2003, 371, 199-204;
41. c) M. A. Fabian, W. H. Biggs III, D. K. Treiber, Nat. Biotechnol. 2005, 23, 329-336;
42. d) Z. A. Knight, K. M. Shokat, Chem. Biol. 2005, 12, 621-637.
43. a) P. J. Morin, BioEssays 1999, 21, 1021-1030;
44. b) P. Cohen, S. Frame, Nat. Rev. Mol. Cell Biol. 2001, 2, 769-776;
45. c) R. S. Jope, G. V. W. Johnson, Trends Biochem. Sci. 2004, 29, 95-102.
46. For a review on potent small organic inhibitors of GSK-3, see: A. Martinez, A. Castro, I. Dorronsoro, M. Alonso, Med. Res. Rev. 2002, 22, 373-384.
47. For cyclin dependent kinases, see: a) M. Knockaert, P. Greengard, L. Meijer, Trends Pharmacol. Sci. 2002, 23, 417-425;
48. b) A. Huwe, R. Mazitschek, A. Giannis, Angew. Chem. 2003, 115, 2170-2187;
49. Angew. Chem. Int. Ed. 2003, 42, 2122-2138.
50. B. M. Trost, C. M. Older, Organometallics 2002, 21, 2544-2546.
51. T. P. Gill, K. R. Mann, Organometallics 1982, 1, 485-488.
52. For optically active organometallic compounds, see: H. Brunner, Angew. Chem. 1999, 111, 1248-1263;
53. Angew. Chem. Int. Ed. 1999, 38, 1194-1208.
54. 50 values against the isoforms of GSK-3. Typically, the introduction of a metal fragment significantly improves the solubility in water/DMSO mixtures.
55. F. Zhang, C. J. Phiel, L. Spece, N. Gurvich, P. S. Klein, J. Biol. Chem. 2003, 278, 33067-33077.
56. M. Leost, C. Schultz, A. Link, Y. Wu, Eur. J. Biochem. 2000, 267, 5983-5994.
57. L. Meijer, A.-L. Skaltsounis, P. Magiatis, P. Polychronopoulos, M. Knockaert, M. Leost, X. P. Ryan, C. A. Vonica, A. Brivanlou, R. Dajani, C. Crovace, C. Tarricone, A. Musacchio, S. M. Roe, L. Pearl, P. Greengard, Chem. Biol. 2003, 10, 1255-1266.
58. K. Satyamoorthy, E. DeJesus, A. J. Linnenbach, B. Kraj, D. L. Kornreich, S. Rendle, D. E. Elder, M. Herlyn, Melanoma Res. 1997, 7, 35-42.
59. K. S. M. Smalley, P. Bradfford, N. K. Haass, J. M. Brandner, E. Brown, M. Heryln, Am. J. Pathol. 2005, 166, 1541-1554.
60. J. Tan, L. Zhuang, H.-S. Leong, N. G. Iyer, E. T. Liu, Q. Yu, Cancer Res. 2005, 65, 9012-9020.
61. R. DasGupta, A. Kaykas, R. T. Moon, N. Perrimon, Science 2005, 308, 826-833.
62. a) S. E. Stachel, D. J. Grunwald, P. Z. Myers, Development 1993, 117, 1261-1274;
63. b) W. Driever, Curr. Opin. Genet. Dev. 1995, 5, 610-618;
64. c) S. van de Water, M. van de Wetering, J. Joore, J. Esseling, R. Bink, H. Clevers, D. Zivkovic, Development 2001, 128, 3877-3888.
65. W. P. Hart, D. Shihua, M. D. Rausch, J. Organomet. Chem. 1985, 282, 111-121.